Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07421544 · ClinicalTrials.gov registry record · Phase 4
Assess Injectable Hyaluronic Acid Gel for the Treatment of Volume Loss, Skin Laxity and Fine Lines
A Phase 4 study, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.
- Not yet
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT07421544 is a Phase 4 study that has not yet begun recruiting, run by Goldman, Butterwick, Fitzpatrick and Groff. The registered enrollment target is 100 participants.
The verdict
NCT07421544, a Phase 4 study, has not yet begun recruiting, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
Clinical trial to assess the real-world effectiveness of Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid (HA) gel for the treatment of mild-to-moderate facial aging, including volume loss, fine lines, and skin laxity, following treatment administered using routine clinical injection techniques over the course of 60 days.
Interventions
- OTHER Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-03-01 |
| Est. Completion | 2026-07-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07421544
The ClinicalTrials.gov registry entry for NCT07421544 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Goldman, Butterwick, Fitzpatrick and Groff, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid is the first listed.
NCT07421544 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07421544 about?
NCT07421544 is a clinical study titled "Assess Injectable Hyaluronic Acid Gel for the Treatment of Volume Loss, Skin Laxity and Fine Lines". Clinical trial to assess the real-world effectiveness of Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid (HA) gel for the treatment of mild-to-moderate facial aging, including volume loss, fine lines, and skin laxity, following treatment administered using routine clinical injection techniques over...
What is the current status of trial NCT07421544?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2026-03-01. Estimated completion is 2026-07-01.
What interventions are being tested in trial NCT07421544?
The interventions under investigation include: Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid (OTHER).
Who is sponsoring clinical trial NCT07421544?
This trial is sponsored by Goldman, Butterwick, Fitzpatrick and Groff, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.